Skip to main content
. 2017 Oct 26;5(11):E1035–E1043. doi: 10.1055/s-0043-117953

Table 1. Baseline characteristics of patients included in this study.

Total FCSEMS FCSEMS + C(R)T P value Plastic stent Plastic stent + C(R)T P value
Total no. of stents, n (%) 291 (100) 100 (66.2) 51 (33.8) n/a 99 (70.7) 41 (29.3) n/a
Age, mean ± SD, years 65.6 ± 10.3 67.3 ± 10.8 65.1 ± 9.1 0.22 66.9 ± 9.2 58.8 ± 10.2  < 0.05
Male, n (%) 185 (63.6) 54 (54) 35 (68.6) 0.08 66 (66.7) 30 (73.2) 0.45
Type of tumor, n. (%) 0.14 < 0.05

  • Pancreas

 241 (82.8) 81 (81) 46 (90.2) 74 (74.7) 40 (97.4)

  • Distal cholangiocarcinoma

 50 (17.2) 19 (19) 5 (9.8) 25 (25.3) 1 (2.4)
Resectability, n (%)  < 0.05 < 0.05

  • Unresectable

 186 (63.9) 52 (52) 45 (88.2) 53 (53.5) 36 (87.8)

  • Resectable

 102 (35.1) 45 (45) 6 (11.8) 46 (46.5) 5 (12.2)

  • Unknown

 3 (1) 3 (3) n/a n/a n/a
Systemic therapy, n (%) n/a n/a

  • None

 199 (68.4) 100 (100) n/a 99 (100) n/a

  • Chemotherapy

 58 (19.9) n/a 37 (72.5) n/a 21 (51.2)

  • Chemoradiotherapy

 34 (11.7) n/a 14 (27.5) n/a 20 (48.8)
Timing of C(R)T, n (%) n/a n/a

  • Neoadjuvant

 20 (21.7) n/a 10 (19.6) n/a 10 (24.4)

  • Palliative

 72 (78.3) n/a 41 (80.4) n/a 31 (75.6)

FCSEMS, fully-covered self-expandable metal stent; C(R)T, chemo(radio)therapy.